Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...

LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.

A labeling mistake has led to a nationwide recall of four different types of Ritz peanut butter cracker sandwich cartons, ...

Hims & Hers Health (HIMS) is quickly becoming one of the most compelling stories in the market as an emerging powerhouse in the direct-to-consumer healthcare space. The stock has posted outsized gains ...

On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

BENGALURU] European shares closed lower on Friday (Jul 11), as losses in banks and healthcare stocks weighed at the end of a ...

The April-June quarter was anything but ordinary for the US stock market, even as the S&P 500 plummeted 13 per cent in April ...

Wockhardt announces its exit from the US generics market, shifting focus to its innovative antibiotic and biologicals ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...